Project Grant K99CA293236
Award Date 8/4/26
Completion Date 7/31/28
Dollars Obligated $135K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90033, USA
Similar Awards
- The National Cancer Institute awarded the University of Southern California $699,303 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify pre-diagnostic epigenetic biomarkers of colorectal cancer risk and understand epigenetic mechanisms of lifestyle and genetic CRC risk factors across multiple U.S. populations. The research will conduct a nested case-control study of 1,500 colorectal cancer cases and 1,500 matched controls drawn from the...
- The National Cancer Institute awarded the University of Southern California $560,863 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of p73-mediated death receptor 5 (DR5) induction in therapeutic response to cyclin-dependent kinase (CDK) inhibition in colorectal cancer. The project examines how CDK inhibitors trigger a signaling cascade in which CDK inhibition leads to p73 dephosphorylation and nuclear translocation, which in turn activates DR5...
- The National Cancer Institute awarded the University of Southern California $254,091 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support postdoctoral training in integrative cancer epidemiology. The award funds a joint training program administered by USC's Norris Comprehensive Cancer Center and the University of Hawaii Cancer Center. The program trains postdoctoral fellows for independent careers in integrative cancer epidemiology research, emphasizing...
- The National Cancer Institute awarded The Leland Stanford Junior University $166,968 on August 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop single-molecule multi-omics sequencing methods for spatially resolved epigenetic profiling of extrachromosomal DNA (ecDNA) molecules and to investigate the relationship between ecDNA spatial organization, epigenetic landscape, and transcriptional regulation. The work addresses a technical gap in understanding ecDNA's...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $581,548 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the therapeutic mechanisms of targeting WRN in microsatellite-instable colorectal cancer. The research will delineate mechanisms by which Werner helicase inhibition triggers cell death in MSI colorectal cancer cells and elucidate the immunological effects of that cell death. The work focuses on...
- The National Cancer Institute awarded The Leland Stanford Junior University $149,353 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to investigate mechanistic pathways through which P53 reactivation can restore tumor suppression in lung adenocarcinoma and identify cooperative drug combinations for improved therapeutic outcomes. The funded research pursues three specific aims: investigating the mechanisms by which P53 reactivation represses KRAS signaling; exploring...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $479,234 on May 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate nonsense-mediated mRNA decay mechanisms in cancer biology. The project explores how nonsense-mediated mRNA decay (NMD) functions beyond its conventional role of degrading faulty transcripts, with three specific aims: decode gene dependencies in cancer cell lines using NMD residual signatures from...
- The National Institutes of Health National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $146,299 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) for a K99 postdoctoral career development grant supporting research into cancer cell surface remodeling and engineered immunotherapy. The funded research investigates how dynamic cell surface changes during cancer progression shape tumor-immune interactions and fibrosis, with particular focus...
- The National Cancer Institute awarded The Leland Stanford Junior University $158,499 on May 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research investigating the role of CDKN2A in lung adenocarcinoma metastasis. The award funds exploration of how CDKN2A inactivation promotes metastatic colonization and growth in oncogenic KRAS-driven lung adenocarcinoma. The research employs CRISPR-CAS9 somatic genome editing and tumor barcoding in genetically engineered mice...
- The National Cancer Institute awarded the University of Southern California $162,501 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support methodological training for social and behavioral research in cancer control. The award funds a T32 training program that will provide six predoctoral trainees per year with innovative methodological training focused on social and behavioral cancer control and prevention research. The program applies novel study design,...